Apr 14

LGC can help develop new medications

ParkinsonsThis week saw World Parkinson’s Day and Dr Christian Zeine from our Standards team has been sharing his thoughts on how we are able to help develop new medications to treat this chronic and progressive disorder.

“With current medical knowledge, Parkinson’s can be treated effectively, but there is no final cure at this stage.

Well known anti-Parkinson’s drugs are nowadays available as generic medicines which help to lower the burden of this cruel disease, for example:

  • levodopa and carbidopa to enhance dopamine levels
  • anticholinergics like procyclidine and trihexylphenidyl, lowering acetylcholine levels to reduce tremor and muscle stiffness
  • COMT inhibitors like entacapon and tolcapon to steady the dopamin levels
  • or MAO-B inhibitors to slow dopamine’s metabolic breakdown

Furthermore, Parkinson’s patients tend to develop specific depressions which can be worsened by the levodopa therapy. Such depressions can be alleviated to some extent with special antidepressants like clozapine and L-tryptophan.

Anti-Parkinson’s reference standards from LGC

In order to help develop cost effective generic medicines to fight Parkinson, LGC offers reference standards for specific anti-Parkinsonian drug substances and their impurities to medicine manufacturers. Like all of LGC’s impurity and API reference standards, they can be used to develop, validate and calibrate analytical methods in pharmaceutical quality control.”

View all our anti-Parkinson’s reference standards here >>

More blogs from our Standards team can be found here >>

Leave a Reply

%d bloggers like this: